ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0462

Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years

Mohanad Elfishawi1, Mahmut Kaymakci2, Sara Achenbach3, Cynthia Crowson4, Tanaz Kermani5, Cornelia Weyand4, Matthew J. Koster1 and Kenneth J. Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Rochester, MN, Rochester, MN, 4Mayo Clinic, Eyota, MN, 5University of California Los Angeles, Los Angeles, CA

Meeting: ACR Convergence 2022

Keywords: Epidemiology, giant cell arteritis, Mortality, population studies, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use of imaging studies on the incidence and outcomes of large artery manifestations remains unclear. In this study, we aimed to investigate incidence trends and outcomes of large artery manifestations in a population-based cohort of patients with GCA over 70 years.

Methods: The study cohort included patients with incident GCA between 1950-2016 in a defined geographical area. Incident large artery manifestations were defined as aortic aneurysm, aortic dissection, stenosis in the aorta, or any of its main branches diagnosed within 1 year prior to the diagnosis of GCA or anytime afterward. Patients were followed till December 31st, 2020, death, or migration. Cumulative incidence of large artery manifestations adjusted for the competing risk of death was estimated. Cox proportional hazards models adjusted for age and sex were used to assess the association of clinical characteristics with large artery manifestations.

Results: The cohort included 289 patients with GCA :222 (77%) females; mean age at diagnosis was 76.4 ± 8.2 years; temporal artery biopsy was positive in 235 patients (81%) and mean ESR was 75.1 (±30.4) mm/hour. Mean follow up period was 10.4 ± 7 years. Incident large artery manifestations developed in 104 patients throughout the follow up period, most were found incidentally on imaging (76%).

Cumulative incidence rates of large artery manifestations at 5 years were 7.3% (95% CI 2.4-22.1%), 15.9% (95% CI 10.6-23.8%) and 27.2% (95% CI 20.2-36.6) for patients diagnosed in 1950-1974, 1975-1999 and 2000-2016, respectively. Moreover, cumulative incidence of large vessel manifestations at 15 years was 14.8% (95% CI 7.0-31.6%), 30.2% (95% CI 23.1-39.4%) and 48.8% (95% CI 38.8-61.3%) for patients diagnosed in 1950-1974, 1975-1999 and 2000-2016, respectively (Figure 1).

Patients with GCA diagnosed in 2000-2016 and 1975-1999 had more than 3.5-fold and 2-fold increase in incidence of large artery manifestations (HR:3.49 95%CI 1.67-7.3 and HR: 1.98 95% CI 0.97–4.07, respectively) compared to 1950-1974. However, there was no significant increase in aortic aneurysm or dissection (Table 1).

Clinical predictors for large artery manifestations included weight loss, fatigue, arm claudication, ever smoker and bruit on physical examination. On the other hand, cranial symptoms were negatively associated with large artery manifestations (Table 2)

Mortality risk has significantly decreased in patients with large artery manifestations diagnosed in 2000-2016 (HR 0.38 95% CI 0.17–0.81) following no significant improvements in 1975-1999 (HR 0.61 95% CI 0.29-1.30) compared to 1950-1974 (reference).

Conclusion: Incidence of large artery manifestations (mainly large artery stenosis) has increased over time likely from increased awareness and greater use of imaging studies. The incidence of aortic aneurysm/dissection has not changed over the last 7 decades. Mortality improvements may be due to earlier detection and identification of large artery manifestations.

Supporting image 1

Figure 1: Cumulative incidence for time to any large artery manifestation in patients with incident GCA 1950_2016 (i.e., earliest of large artery stenosis or aortic aneurysm or aortic dissection) adjusted for the competing risk of death. Patients with an event>365 days before the diagnosis date were excluded.

Supporting image 2

Table 1: Cox proportional hazards model showing Age- and Sex- adjusted time to large artery manifestation among patients with incident GCA 1950_2016

Supporting image 3

Table 2: Clinical predictors with the earliest date of large artery manifestation in patients with incident GCA 1950_2016.


Disclosures: M. Elfishawi, None; M. Kaymakci, None; S. Achenbach, None; C. Crowson, None; T. Kermani, None; C. Weyand, None; M. Koster, None; K. Warrington, Eli Lilly, GlaxoSmithKlein(GSK), Kiniksa, Chemocentryx.

To cite this abstract in AMA style:

Elfishawi M, Kaymakci M, Achenbach S, Crowson C, Kermani T, Weyand C, Koster M, Warrington K. Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/increasing-incidence-of-large-artery-manifestations-in-patients-with-giant-cell-arteritis-a-population-based-cohort-over-70-years/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-incidence-of-large-artery-manifestations-in-patients-with-giant-cell-arteritis-a-population-based-cohort-over-70-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology